WO1994008034A1 - Novel hirudine variant, process for producing the same, and anticoagulant containing the same as active ingredient - Google Patents
Novel hirudine variant, process for producing the same, and anticoagulant containing the same as active ingredient Download PDFInfo
- Publication number
- WO1994008034A1 WO1994008034A1 PCT/JP1993/001384 JP9301384W WO9408034A1 WO 1994008034 A1 WO1994008034 A1 WO 1994008034A1 JP 9301384 W JP9301384 W JP 9301384W WO 9408034 A1 WO9408034 A1 WO 9408034A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hirudin
- mutant
- amino acid
- asp
- glu
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- the present invention relates to a novel hirudin mutant having an amino acid sequence different from a naturally occurring hirudin mutant.
- the present invention relates to a DNA having a DNA sequence encoding the polypeptide having the novel amino acid sequence.
- the present invention provides a novel hirudin mutant expression vector for expressing the novel hirudin mutant, a transgenic Escherichia coli transformed with the expression vector, and a transgenic Escherichia coli.
- the present invention relates to a method for producing a hirudin mutant by producing and secreting a hirudin mutant using enterobacteria.
- the present invention relates to an anticoagulant having at least one novel hirudin mutant having the novel amino acid sequence as an active ingredient.
- Hirudin is an antithrombin-active polypeptide isolated from the secretion from the salivary gland of medicinal leech (Hirudo medicinalis).
- Three naturally occurring hirudin mutants are known: HV1, HV2 and HV3.
- the amino acid sequences of the polypeptides that make up these naturally occurring hirudin mutants have been elucidated.
- the gene encoding the amino acid sequence was also obtained as a c-DNA by Kuguchi-Jung, and its DNA sequence was also elucidated.
- the expression vector 3 ⁇ 4-Escherichia coli (Escherichia coli) is also introduced into a host microorganism such as yeast (Saccharoyces cerevisiae) to express the polypeptide constituting the hirudin mutant.
- hirudin mutant in which the amino acid sequence was artificially mutated was produced.
- HV2 Lys 47
- HV1 exhibits high activity comparable to the antithrombin activity of natural HV1.
- a mutant obtained by replacing the amino acid sequence of the natural N-terminal region of HV1 with another amino acid, or obtained by adding an amino acid to the N-terminal HV1-like hirudin mutants such as mutants have also been produced.
- the amino acid sequence of the N-terminal region of hirudin is the active site of the cleavage enzyme of the polypeptide chain of tobin.
- the present inventors can obtain the amino acid sequence of the polypeptide constituting the above natural hirudin mutant by artificially performing a point mutation (point mutation). Based on an idea different from that of the hirudin mutant, hybrid type mutant HV1C3 in which the partial polypeptide of the C-terminal region of HV1 was replaced with the partial polypeptide of the C-terminal region of HV3, etc. Especially, the above-mentioned hybrid type hilge The mutant HV1C3 was found to exhibit higher antithrombin activity than HV1 (JP-A-4-173798).
- these complexed hirudin mutants exhibiting high anti-thrombin activity have pharmacological properties as anticoagulants that inhibit the clotting process caused by cleavage of the polypeptide chains by thrombin. Clarified that it is effective. That is, it has been clarified that since it has antithrombin activity (the ability of thrombin to inhibit the enzyme activity of cleaving polypeptide polypeptide), it is possible to inhibit and inhibit the formation of blood clots.
- an anticoagulant containing the above-mentioned complex type hirudin mutant HV1C3 or the like proposed in the earlier application as an active ingredient is one of pure hirudin mutants having a predetermined pharmacological equivalent. It was found that its pharmacological activity apparently changed when prepared as such and stored at room temperature for a long time.
- the present invention is intended to solve the above-mentioned problems caused by the formation of a succinimido compound or a ⁇ transfer compound. That is, an object of the present invention is to replace a aminoic acid sequence which is liable to form a succinimide form or // transformation form with another aminoic acid sequence to obtain a hirudin derivative. An object of the present invention is to provide a novel hirudin mutant which can suppress conversion into analogs and has high antithrombin activity.
- the present invention provides an anti-toxin that is so high that it can compensate for the decrease in the concentration of the hirudin mutant associated with the conversion to the hirudin analog due to the formation of a succinimide compound or a transition compound.
- An object of the present invention is to provide a novel hirudin mutant having oral bin activity.
- An object of the present invention is to suppress the decrease in the concentration of the hirudin mutant associated with the conversion to a hirudin analog due to the formation of a succinimide or ⁇ transferant, thereby providing a pharmacological effect.
- the decrease in activity is within an acceptable range, the increase in the total concentration of hirudin in the anticoagulant is suppressed, or when the concentration of the hirudin mutant is reduced due to conversion to a hirudin analog.
- a novel hirudin mutant having high antithrombin activity and capable of suppressing an increase in the total concentration of hirudin in the anticoagulant necessary for obtaining the desired pharmacological activity It is to provide The present invention provides a novel amino acid sequence represented by the following general formula I: It concerns a regular hirudin mutant.
- A3 represents Lys or Glu.
- A4 represents Asp, Asn or Gin
- A5 represents Ala or Gly
- A6 represents Glu or Glu.
- Lys represents Lys or Asp
- A8 represents Asp or Glu
- A9 represents Ala, Tyr or a bond
- A10 represents Tyr or Leu, respectively, and either A9 or A10 is Tyr.
- the hirudin mutant represented by the above general formula I of the present invention can be roughly classified into two groups due to a difference from the amino acid sequence of the hirudin mutant HV1C3 characterizing the amino acid sequence. It is possible. That is, the first group, Asp 33 -Gly Ru contained in A Mi acid sequence of hirudin variants HV1C3 34 - parts and Asp 62 - Ala 63 - parts, Complex No A Mi the two Asp A group consisting of hirudin mutants obtained by artificially performing a point mutation on either or both of the amino acid partial sequences.
- the novel hirudin mutant of the present invention can be obtained by modifying the amino acid sequence of the hirudin mutant HV1C3 with respect to the amino acid sequence. It is something that can be done.
- the helgin mutant of the present invention has the following features.
- mutants can you roughly classified into the first group, ⁇ Ma are in other words Hiruji emission variants A Mi acid sequence of HV1C3 - Gly 34 - And / or the Asp- 6Z Ala fc 3- and / or the amino acid partial sequence containing these two Asp's by artificially performing a point mutation.
- the resulting hirudin mutant is one in which the conversion to the hildin analog by the formation of a succinimide or / transform is suppressed.
- novel hirdin mutant of the present invention provides a pharmacological action as an anticoagulant due to the antithrombin activity of the hirdin mutant HV1C3, and thus the antithrombin activity.
- the amino acid sequence is largely conserved, and it is naturally expected that the process of loss from the blood by metabolism will not differ from that of the virgin mutant HV1C3.
- the characteristics of the novel hirudin mutant of the present invention in which the conversion to a hirudin analog by the formation of a succinimide or /?-Transformant is suppressed, Robin activity, especially
- the characteristic of increasing the reaction rate of forming a complex with thrombin is that the amino acids are brought about by the modification of the amino acid partial sequence of each valence, and also occur without mutual interference. is there.
- the present invention provides a DNA encoding the amino acid sequence of such a hirudin mutant, for example, a compound represented by the general formula:
- GAA (6) is GCG TAC or binding
- (7) is TAC
- the present invention provides a promoter, a DNA sequence encoding a signal peptide, a DNA sequence encoding a polypeptide having an amino acid sequence represented by the general formula I, and a transcription termination signal.
- the present invention relates to a novel hirudin mutant expression vector comprising a DNA sequence and a DNA sequence containing a replication initiation signal.
- the present invention relates to a novel transgenic Escherichia coli transformed by the hirudin mutant expression vector.
- the present invention provides a method for culturing the above-mentioned recombinant Escherichia coli in a medium, and ingesting a hirudin mutant having an amino acid sequence represented by the general formula I from the cultured cells and the medium. And a method for producing a novel hirudin mutant.
- the hirudin mutant represented by the above general formula I of the present invention may be produced by chemical synthesis or may be produced by a genetic engineering technique.
- the hirudin mutant secretion plasmid PMTSHV1C3 (see Japanese Patent Laid-Open Publication No. 4-798) was digested with a restriction enzyme to remove the DNA sequence encoding the amino acid sequence at positions 31 to 44.
- a DNA sequence encoding the sequence of positions 31 to 44 of the amino acid sequence represented by the general formula I is chemically synthesized. From this plasmid PMTSHV1C3, the DNA excluding the D sequence encoding the amino acid sequence at positions 31 to 44 of the hirudin mutant HV1C3, and the chemically synthesized sequence at positions 31 to 44 of the general formula I were used.
- each of these plasmids is cleaved with a restriction enzyme to remove the DNA sequence encoding the amino acid sequence at positions 45 to 66.
- a DNA sequence encoding the sequence from position 45 to position 66 of the amino acid sequence represented by the general formula I is chemically synthesized.
- a plasmid pCX397DAl comprising a DNA encoding the amino acid sequence of the hirudin mutant of the present invention, which is reacted with chemically synthesized DNA encoding the sequence from position 66 to position 66 using DNA ligase or the like.
- plasmids contain a promoter derived from plasmid PMTSHV1C3, a DNA sequence encoding a signal peptide, a transcription termination signal, and a DNA sequence encoding the hirudin mutant of the present invention. It is inserted between the DNA sequence encoding the peptide and the transcription termination signal.
- Escherichia coli is transformed with these plasmids.
- the hirudin mutant of the present invention is produced in the cells and the medium.
- the hirudin mutant of the present invention is not limited to the above-described host and vector system, and may be produced using a host and vector system generally known as a genetic engineering technique.
- suitable microbial host strains include the above-mentioned Escherichia coli strain, Bacillus subtilis (Bac i 11 us subti 1 ⁇ ) and yeast (Saccharomyces cerevisiae) strains, and expression according to each host cell is included.
- the hirudin mutant can be produced by using the vector.
- the hirudin mutant of the present invention can be isolated by a generally known method and then subjected to chromatography, reverse phase HPLC. Purify by other purification methods.
- hirudin mutant In the obtained hirudin mutant, the formation of succinimide or ⁇ transferant was suppressed more than in hirudin HV1 and hirudin mutant HV1C3 (Japanese Patent Application Laid-Open No. 4-173798). Therefore, the stability is high. In addition, it maintains high antithrombin activity.
- a well-known anticoagulant can be obtained by preparing a preparation by a method generally known as a method for producing a preparation. That is, the hirudin mutant of the present invention is prepared by any conventional method using any conventional pharmaceutical carrier or excipient.
- Administration can be, for example, intravenous, intradermal, subcutaneous or intramuscular, and topical parenteral. The dosage is determined as appropriate according to the individual case, taking into account the symptoms, age of the subject, gender, etc., and is usually 0.1 to 100 mg per adult per day, 1 to several times a day. Administer separately.
- the novel hirudin mutant of the present invention is obtained by modifying the amino acid sequence of the hirudin mutant HV1C3 to the amino acid sequence, and belongs to the first group.
- the total amount of hirudin to be contained in the coagulant is at least less than the anticoagulant with the conventional hirudin mutant HV1C3.
- the conventional anticoagulant using the hirudin mutant HV1C3 has the disadvantage that the total amount of hirudin to be owned must be increased in advance to compensate for the decrease in pharmacological activity during storage. It is useful as an effectively improved anticoagulant.
- the novel hirudin mutant is produced by a genetic engineering technique in the same manner as the conventional hirudin mutant HV1C3, so that it can be produced in large quantities and with high reproducibility. It can be produced, and accordingly, can be produced at low cost.
- FIG. 1 shows a conceptual diagram of a method for constructing a hirudin mutant CX397DA secretion plasmid PCX397DA.
- FIG. 2 shows the nucleotide sequence of a synthetic DNA encoding a part of the hirudin mutant used in the present invention.
- FIG. 3 shows a conceptual diagram of a method for constructing a hirudin mutant CX397NA secretion plasmid PCX397NA.
- Fig. 4 shows a conceptual diagram of the construction method of plasmid PCX397N.
- Figure 5 shows a conceptual diagram of a plus Mi de PCX397DA1, P CX397DA2, P CX397DA3, PCX397NA1, PCX397NA2, pCX397NA3, PCX397N1, how to build a P CX397N2 and PCX397N3.
- FIG. 6 shows the nucleotide sequence of a synthetic DNA encoding a part of the hirudin mutant used in the present invention.
- FIG. 7 shows a conceptual diagram of a method for preparing a hirudin mutant gene, introducing the gene into a secretion expression plasmid pMTS HV19 or pMTS HV10, and transforming the JM109 or RR1 strain with the gene.
- FIG. 8 shows a conceptual diagram of a method for constructing a hirudin mutant gene having two or more mutations. (Indicates the hirudin gene)
- FIG. 9 shows a conceptual diagram of a method for constructing the hirudin mutant HV115 gene.
- FIG. 10 shows a conceptual diagram of a method for constructing a hirudin mutant HV116 gene.
- the transformed Escherichia coli was deposited with the Microorganisms and Technology Research Institute of the Ministry of International Trade and Industry of the Ministry of International Trade and Industry (hereinafter referred to as the Microtechnology Research Institute), and the accession number of the Microtechnology Research Institute was No. 3984 (FERM BP). -3984).
- Plasmid pCX397NA was constructed according to the method shown in FIG. First, in order to obtain a DNA fragment corresponding to positions 31 to 44 of the helgin mutant CX397NA, two types of oligonucleotides shown in Fig. 2 (B) were used to produce DNA fragments. (Model 380B) using the phosphoric acid amidite method. After deprotection, Each oligonucleotide was purified by crystallization gel electrophoresis.
- the transformed Escherichia coli was deposited with the micro-organisms, and the accession number was obtained from the micro-organisms, No. 3980 (FERM BP-3980).
- Plasmid PCX397N was constructed according to the method shown in FIG. First, the plasmid PUCHV3 (described in Reference Example of JP-A-4-173798) was digested with restriction enzymes Aval and Kpnl to obtain a DNA fragment corresponding to positions 31 to 44 of the hirudin mutant CX397N. And fragments lOpmol this, cut plus Mi de pMTSH VI C3 and (same publication) 5 Opmol the T 4 DNA ligase in Complex free solution 100] with restriction enzyme Aval and Kpnl, at 16 ° C The reaction was performed for 30 minutes.
- the reaction liquid 10; Escherichia coli JM109 strain was transformed with the / 1, to obtain a Hiruji emissions mutant CX397N secretory expression plus Mi de P CX397N.
- the nucleotide sequence was confirmed by a method such as Sanger.
- the transformed Escherichia coli was deposited with the micro-organisms, and the accession number was obtained from the micro-organisms No. 3976 (FERM BP-3976).
- Plasmid PCX397DA1 was constructed according to the method shown in FIG. First, in order to construct a DNA fragment corresponding to the C-terminal amino acid of the hirudin mutant CX397DA1, the four types of oligonucleotides (1-1, 1-2, 1-3, 1-4) were synthesized. Deprotected Then, each of the oligonucleotides was purified by polyacrylamide electrophoresis.
- the transformed Escherichia coli was deposited with the micro-organisms, and the accession number was obtained from the micro-organisms No. 3985 (FEBM BP-3985). .
- Plasmid pCX397DA2 was constructed according to the method shown in FIG. First, in order to construct a DNA fragment corresponding to the C-terminal amino acid of the hirudin mutant CX397DA2, four types of oligonucleotides shown in FIG. 6 (2) were synthesized. After deprotection, each of the oligonucleotides was purified by polyacrylamide gel electrophoresis.
- the transformed Escherichia coli was deposited with the Micro-Institute, and the accession number No. 3986 of Micro-Institute was obtained (FERM BP-3986).
- Plasmid PCX397DA3 was constructed according to the method shown in Fig. 5.
- the transformed Escherichia coli was deposited with the Micro Investigator to obtain an accession number, Micro Invest. No. 3987 (FERM BP-3987).
- Plasmid PCX397NA1 was constructed according to the method shown in FIG. First, in order to construct a DNA fragment corresponding to the C-terminal amino acid of hirudin mutant CX397NA1, four types of oligonucleotides shown in FIG. 6 (1) were synthesized. After deprotection, each of the oligonucleotides was purified by polyacrylamide gel electrophoresis.
- Plasmid PCX397NA2 was constructed according to the method shown in FIG. First, in order to construct a DNA fragment corresponding to the C-terminal amino acid of hirudin mutant CX397NA2, four types of oligonucleotides shown in Fig. 6 (2) were synthesized. After deprotection, each oligonucleotide was purified by polyacrylamide gel electrophoresis. .
- each of the four types of oligonucleotides was mixed with 2 pmo1, and then annealed. A fragment was obtained. This fragment and the restriction enzymes Kpnl and Hindlll
- the transformed Escherichia coli was deposited with the micro-organisms, and the accession number was obtained from the micro-organisms No. 3982 (FERM BP-3982).
- Plasmid pCX397N1 was constructed according to the method shown in FIG. First, in order to construct a DNA fragment corresponding to the C-terminal amino acid of the hirudin mutant CX397N1, four types of oligonucleotides shown in Fig. 6 (1) were synthesized. After deprotection, each oligonucleotide was purified by polyacrylamide electrophoresis.
- the transformed Escherichia coli was deposited with the micro-organisms, and the accession number was obtained from the micro-organisms No. 3977 (FERM BP-3977).
- the plasmid pCX397N2 was constructed according to the method shown in FIG. First, in order to construct a DNA fragment corresponding to the C-terminal amino acid of hirudin mutant CX397N2, four types of oligonucleotides shown in Fig. 6 (2) were synthesized. After deprotection, each of the oligonucleotides was purified by polyacrylamide gel electrophoresis.
- the transformed Escherichia coli was deposited with the Micro Invest., And the accession number No. 3978 of Micro Invest. (FERM BP-3978) was obtained.
- the plasmid pCX397N3 was constructed according to the method shown in FIG. First, in order to construct a DNA fragment corresponding to the C-terminal amino acid of the hirudin mutant CX397N3, four kinds of oligonucleotides shown in Fig. 6 (3) were synthesized. After deprotection, each oligonucleotide was purified by polyacrylamide gel electrophoresis.
- the transformed Escherichia coli was deposited with the micro-organism, and the accession number was obtained from micro-organisms, No. 3979 (FERM BP-3979).
- the E. coli JM109 strain (Examples 11) to 12) transformed with the hirudin mutant secretion expression plasmid was separately treated with 100 g / ml ampicillin.
- the cells were cultured in 100 ml of a 2xTY medium containing 16 g / l of bactotripton, 10 g of lactose extract and 1 g of NaCl. After shaking culture at 37 ° C for 24 hours, the cells were collected. Each sample of the precipitated cells were suspended in 25% Shiyuku loin 50mM Tris ⁇ HC1 (P H7.5) 1 mM EDTA in 100 ml, at room temperature Treated for 10 minutes.
- the cells After collecting cells by centrifugation at 10,000 Xg for 10 minutes, the cells were suspended in 100 ml of cold water and subjected to osmotic shock to release substances in the periplasmic space of the cells. After removing cells by centrifugation at 10,000 Xg for 10 minutes, the periplasmic fraction was filtered using a 0.22 ⁇ m filter.
- the crudely purified hirudin mutant sample and the hirudin mutant HV1C3 (control) obtained in Example 2 were stored at 25'C for 4 weeks, and then fractionated using a reversed-phase high-speed liquid chromatogram. The results were compared with the results before storage.
- the content of the succinimide or /? Transition was calculated as follows. Hirujin Peaks detected within 4 minutes before and after the elution time of the mutant peak are regarded as succinimides or transitions, and out of the sum of the peak areas of these and the hirudin mutant, The percentage occupied by the peak area of the succinimide or metamorphic form was defined as its content. That is,
- the helgin mutant of the present invention was 25. Even when stored in C, the production of the succinimide compound or the pentatransformant can be significantly reduced in comparison with the previously known virgin mutant HV1C3, and its efficacy is high. It turned out to be stable.
- the hirudin mutant was purified using the following method.
- the Escherichia coli JM109 strain transformed with the virgin mutant secretion expression plasmid was transformed into a 2xTY medium (bactriptone 16g / ml) containing 50 ⁇ g / ml ampicillin.
- the cells were cultured with shaking at 500 ° C for 1 hour at 37 ° C with 500 ml of loctinoist extract extract (lOg / K NaCl 5g / l).
- the periplasmic fraction obtained as described above was separated and eluted under the following conditions using a reversed-phase high-performance liquid chromatogram, and the peak of the hildin mutant was collected.
- Antithrombin activity measurement of specific activity by the chromogenic technique
- the specific activity is determined by a colorimetric assay for the inhibition of hydrolytic activity of thrombin, a synthetic substrate chromozym TH (Toshinoreguri sinoleprolinolenoreginin 4--2-toroanilide acetate, manufactured by Behringer Mannheim).
- a colorimetric assay for the inhibition of hydrolytic activity of thrombin, a synthetic substrate chromozym TH Toshinoreguri sinoleprolinolenoreginin 4--2-toroanilide acetate, manufactured by Behringer Mannheim).
- Antithrombin activity measurement of inhibition constant using a fluorescent synthetic substrate
- Each of the solutions to be added was adjusted so that the concentrations of C so and human thrombin C E0 became the respective predetermined concentrations.
- Time t at which the above-mentioned human bottle solution was added and stirred.
- the light intensity at a wavelength of 450 nm of the fluorescence emitted from the reaction solution was measured.
- the difference between the light intensity measured in the reaction solution and the light intensity measured in the reaction solution having zero concentration of tobin and hirudin is represented by time t.
- a curve called “progress curve j” was obtained.
- This “progress curve” was obtained by comparing the synthetic substrate with thrombin.
- the change in the concentration of the complex of the synthetic substrate and thrombin represented by the “progress curve” was measured by SR Stone et al. [See Biochemistry (1986), 25, p.2622-2628. Or Biochemistry (1979), 18, p.2567-2573] and a complex of hirudin and thrombin was obtained.
- Ki apparent dissociation constant
- Ki is calculated using the relationship between the apparent dissociation constant' and the dissociation constant ⁇ shown in the following equation (1). I asked. The measurement was performed three times for each sample.
- Table 2 shows the dissociation constants Ki (PM) of each hirudin mutant and thrombin complex. This smaller dissociation constant Ki indicates higher anti-thrombin activity.
- the hirudin mutant of the present invention is a hirudin mutant that exhibited the high antithrombin activity previously proposed by the present applicant. Is
- antithrombin has almost the same or higher anti-thrombin activity than HV1C3.
- Mutagenic primers 1 and 2 having the above DNA sequences were synthesized by a phosphoric acid amidite method using an Applied ⁇ Biosystems (model 380B) synthesizer.
- Hirudin HV1 secretion expression vector pMTSHVl Japanese Patent Application No. 2-3030966
- About ⁇ g was digested with 36 units of restriction enzyme EcoRI and 60 units of restriction enzyme HindEI.
- Approximately 250 bp DNA fragment encoding phoA signal, peptide and hirudin HV1 was separated and purified by agarose gel electrophoresis.
- the mutagenic primers 1 and 2 were phosphorylated at the 5 'end using a method similar to the method described in Japanese Patent Application No. 3-63909.
- a mutant DNA (named M13SHV19) was prepared using the aforementioned M13SHV1 and the above 5′-phosphorylated mutant primer 1.
- M13SHV1 and A mutant DNA (designated M13SHV10) was prepared using 5'-phosphorylated primer 2.
- a kit manufactured by Amersham was used.
- the hirudin mutant HV17 secretion expression vector PMTSHV17 Japanese Patent Application No. 3-63909 was digested with the restriction enzyme EcoR I-Hind HI and subjected to agarose gel electrophoresis to obtain a 2.2 Kb vector. One DNA fragment was separated and purified.
- Double-stranded M13SHV19 DNA is digested with the restriction enzyme EcoR I -Hind HI, and an approximately 250 bp DNA fragment encoding phoA signal peptide and hirudin mutant HV-1-9 is separated by agarose gel electrophoresis-purification did. Similarly, a purified DNA fragment of about 250 bp encoding phoA signal peptide and hirudin mutant HV-1-10 was obtained from IU3SHV10 DNA.
- pHTSHVIO a mutant expression plasmid pHTSHVIO was obtained in the same manner.
- the nucleotide sequence was confirmed by a method such as Sanger. (See Fig. 7)
- the transformed Escherichia coli was deposited with the Ministry of International Trade and Industry, National Institute of Advanced Industrial Science and Technology, and obtained accession number FERM-4413.
- periplasmic fraction obtained as in (b) above was concentrated to about 100 by ultrafiltration. This was loaded onto a reverse-phase HPLC column under the following conditions, eluted, fractionated and freeze-dried to obtain hirudin mutant HV-1-15.
- Solvent A. 0.05% trifluoroacetic acid / water
- the plasmid PMTSHV1C3 was also cleaved with restriction enzymes BamHI and HindIII in the same manner, and an approximately 150 bp fragment containing the DNA sequence encoding the C-terminal part of hirudin HV-3 was separated and purified. did.
- the transformed Escherichia coli was deposited with the Research Institute of Biotechnology and Industrial Technology of the Ministry of Trade and Industry to obtain an accession number FERM BP-4412.
- the hirudin mutant HV-1-16 was purified using the same method as described in JP-A-4-282474.
- the antithrombin activity of hirudin mutants HV-1-15 and HV-1-16 was measured using the same method as described in JP-A-4-282474. Table 3 shows the results.
- Table 4 shows the composition of these amino acids.
- the hirudin mutant HV-1-9 (the Val'-Val 2-of the hirudin mutant HV-1 lie 2- ) was transformed using a recombinant microorganism obtained by transforming Escherichia coli JM109 strain with the mutant expression plasmid PMTSHV19.
- the hirudin mutant HV-1-10 (in which lysine 27 of hirudin mutant HV-1 was replaced with Glu Z7 ) is a gene obtained by transforming Escherichia coli JM109 with the mutant expression plasmid PMTSHVIO.
- hirudin mutant HV-1-14 Hirgin mutant HV-1 in which Va-Val 2 -is replaced with lie 1 -lie 2 -and Lys 27 is replaced with Glu 27
- E. coli JM109 strain was transformed with the mutant expression plasmid PMTSHV114, and each of the recombinant microorganisms was cultured using the recombinant microorganism. Separated and purified.
- HV-1-1-5 and HV-1-1-16 are the same as those previously proposed by the present applicant for high antithrombin activity. It can be seen that it shows higher antithrombin activity than HV1C3, which is the body.
- the purified hirudin mutant obtained in Example 4 was desalted with Sephadex G25 (manufactured by Pharmacia), and then aseptically filtered through a 0.22 m filter. . This solution was freeze-dried, and the obtained powder was dissolved in physiological saline to obtain a preparation that could be used as an injection.
- the present invention relates to a hirudin variant respectively representing two groups characterized by modification of the amino acid sequence and a method for producing the same.
- the virgin mutants belonging to both of the two groups can be prepared according to the amino acid sequence according to the above-mentioned production method.
- a person skilled in the art can prepare a DNA sequence encoding a peptide and further construct an expression vector containing the DNA sequence by those skilled in the art using only the contents described in the above specific examples. It is.
- virgin mutants that belong to either of the two groups have their succinimide or metastasis characteristics, which are characteristic of each of the two groups, suppressed from being converted to hildin analogs. It is evident, without giving specific examples, that the combination of the characteristics of the present invention and the characteristics of the anti-Mouth bin bin activity, particularly the reaction rate of forming a complex with the Mouth bin bin. is there.
- the novel hirudin mutant of the present invention is characterized in that the physiologic mechanism that produces its antithrombin activity is a hirudin mutant that has a high similarity in the amino acid sequence. It is clear that it is the same as HV1C3, and it is also clear that its pharmacological action as an anticoagulant (only with a difference in its activity) and its metabolic activity are very similar .
- the present invention provides a novel hirudin mutant.
- the hirudin mutant of the present invention has a higher anti-thrombin activity than the conventional hirudin mutant HV1C3, and exhibits a pharmacological activity due to the formation of a succinimide or a metastasis during storage. Prevents lowering and is useful as an anticoagulant.
- A3 Lys or Glu
- A4 Asp, Asn or Gin
- A6 Glu or Lys
- A9 Ala, Tyr or bond
- A10 Tyr or Leu
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93921080A EP0625580A4 (en) | 1992-09-28 | 1993-09-28 | Novel hirudine variant, process for producing the same, and anticoagulant containing the same as active ingredient. |
US08/861,459 US5972648A (en) | 1993-09-28 | 1997-05-22 | Hirudin analogs, methods of manufacture thereof and anticoagulant compositions having these as active ingredients |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP4/282474 | 1992-09-28 | ||
JP28247492 | 1992-09-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994008034A1 true WO1994008034A1 (en) | 1994-04-14 |
Family
ID=17652907
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1993/001384 WO1994008034A1 (en) | 1992-09-28 | 1993-09-28 | Novel hirudine variant, process for producing the same, and anticoagulant containing the same as active ingredient |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0625580A4 (ja) |
CA (1) | CA2124330A1 (ja) |
WO (1) | WO1994008034A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972648A (en) * | 1993-09-28 | 1999-10-26 | Japan Energy Corporation | Hirudin analogs, methods of manufacture thereof and anticoagulant compositions having these as active ingredients |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02121934A (ja) * | 1988-09-21 | 1990-05-09 | Ciba Geigy Ag | 組合せ医薬組成物 |
JPH02145526A (ja) * | 1988-10-06 | 1990-06-05 | Ciba Geigy Ag | 抗血液凝固剤に対する解毒剤 |
JPH04173798A (ja) * | 1990-11-08 | 1992-06-22 | Nikko Kyodo Co Ltd | ヒルジン変異体,その製造法及び抗凝血剤 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05310788A (ja) * | 1992-04-30 | 1993-11-22 | Japan Energy Corp | ヒルジンの類縁体及び抗凝血剤 |
-
1993
- 1993-09-28 WO PCT/JP1993/001384 patent/WO1994008034A1/ja not_active Application Discontinuation
- 1993-09-28 EP EP93921080A patent/EP0625580A4/xx not_active Withdrawn
- 1993-09-28 CA CA 2124330 patent/CA2124330A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02121934A (ja) * | 1988-09-21 | 1990-05-09 | Ciba Geigy Ag | 組合せ医薬組成物 |
JPH02145526A (ja) * | 1988-10-06 | 1990-06-05 | Ciba Geigy Ag | 抗血液凝固剤に対する解毒剤 |
JPH04173798A (ja) * | 1990-11-08 | 1992-06-22 | Nikko Kyodo Co Ltd | ヒルジン変異体,その製造法及び抗凝血剤 |
Non-Patent Citations (1)
Title |
---|
See also references of EP0625580A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5972648A (en) * | 1993-09-28 | 1999-10-26 | Japan Energy Corporation | Hirudin analogs, methods of manufacture thereof and anticoagulant compositions having these as active ingredients |
Also Published As
Publication number | Publication date |
---|---|
EP0625580A1 (en) | 1994-11-23 |
CA2124330A1 (en) | 1994-04-14 |
EP0625580A4 (en) | 1994-12-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wagenbach et al. | Synthesis of wild type and mutant human hemoglobins in Saccharomyces cerevisiae | |
EP1335938B1 (en) | Apolipoprotein construct | |
JP2894354B2 (ja) | 組換えdna技術によつて産生されたウシ膵臓トリプシン阻害剤の変異型、それらの方法、発現ベクターおよび組換え宿主、およびそれらの製薬学的使用 | |
FI107539B (fi) | Menetelmä yhdistelmä-humaani-hyytymistekijä VIII:n johdannaisen valmistamiseksi ja menetelmässä käytettävä DNA-jakso, vektori ja isäntäsolu | |
JP2750257B2 (ja) | アルファ−1−抗トリプシンに於ける部位特異性突然変異誘発 | |
AU592486B2 (en) | Pancreatic secretory trypsin inhibitor and variants thereof produced by a recombinant host, process, expression vector and recombinant host therefore and pharmaceutical use thereof | |
KR0156246B1 (ko) | 프로테이나제 억제제, 그의 제조방법 및 그를 함유한 의약 | |
CA2385857C (en) | C peptide for improved preparation of insulin and insulin analogs | |
JPH05503627A (ja) | ヘモグロビンおよびその類似体の細菌および酵母での生成 | |
KR0139629B1 (ko) | 미니-프로인슐린, 이의 제조방법 및 용도 | |
JPH05501799A (ja) | 融合タンパク質、その調製及び用途 | |
AU2002213843A1 (en) | Apolipoprotein analogues | |
FI100250B (fi) | Hirudiinijohdannaisten eritys | |
FI107928B (fi) | Erityskuljetin hirudiinin tai hirudiinianalogin tuottamiseksi, kyseessä olevan kuljettimen sisältävät muutetut mikro-organismit, sekä hirudiinin tai hirudiinianalogin valmistusmenetelmä | |
US20230043898A1 (en) | Fusion protein of z-domain and calsequestrin, having improved reactivity, stability, and antibody recovery, and method for isolation and purification of antibody using same | |
WO1994008034A1 (en) | Novel hirudine variant, process for producing the same, and anticoagulant containing the same as active ingredient | |
WO1994019371A1 (fr) | Nouveau peptide presentant une activite inhibitrice de l'elastase et son procede de production | |
AU685835B2 (en) | High molecular weight desulphatohirudin | |
JPH05213998A (ja) | 新規なポリペプチド及びこれを有効成分とする 医薬組成物 | |
HUT51671A (en) | Process for producing new proteins | |
Yang et al. | Modification and characterization of a new recombinant marine antimicrobial peptide N2 | |
JP2012511309A (ja) | Ec−sodのカルボキシル末端のアポプチンタンパク質導入ドメインの融合蛋白質 | |
US5972648A (en) | Hirudin analogs, methods of manufacture thereof and anticoagulant compositions having these as active ingredients | |
CN115572329B (zh) | 一组活性增强代谢较慢的菲牛蛭基因重组水蛭素及其制备方法 | |
JPH04173798A (ja) | ヒルジン変異体,その製造法及び抗凝血剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2124330 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1993921080 Country of ref document: EP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1993921080 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1994 244361 Country of ref document: US Date of ref document: 19941212 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 1997 861459 Country of ref document: US Date of ref document: 19970522 Kind code of ref document: A |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993921080 Country of ref document: EP |